Reply to Chen et al, Uchikoba et al, Siberry et al, and Vuorio et al
- PMID: 35975657
- DOI: 10.1093/cid/ciac668
Reply to Chen et al, Uchikoba et al, Siberry et al, and Vuorio et al
Conflict of interest statement
Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Epidemiological Study of the Effectiveness of Paxlovid.Clin Infect Dis. 2022 Dec 19;75(12):2278. doi: 10.1093/cid/ciac664. Clin Infect Dis. 2022. PMID: 35975644 No abstract available.
-
Methodological Concerns Regarding a Retrospective Study With Real-World Data on Paxlovid in Israel.Clin Infect Dis. 2022 Dec 19;75(12):2278-2279. doi: 10.1093/cid/ciac665. Clin Infect Dis. 2022. PMID: 35975645 No abstract available.
-
Statin Needs to be Continued During Paxlovid Therapy in COVID-19.Clin Infect Dis. 2022 Dec 19;75(12):2281-2282. doi: 10.1093/cid/ciac667. Clin Infect Dis. 2022. PMID: 35975652 Free PMC article. No abstract available.
-
Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy.Clin Infect Dis. 2022 Dec 19;75(12):2279-2281. doi: 10.1093/cid/ciac666. Clin Infect Dis. 2022. PMID: 35975658 No abstract available.